VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Martin on Potential of Immunotherapy in MCL Landscape

Peter Martin, MD
Published: Friday, Aug 18, 2017



Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of modern immunotherapies in the landscape of mantle cell lymphoma (MCL).

Immunotherapy has been in the field of MCL for a long time, Martin explains, with rituximab (Rituxan). However, when discussing the modern era of immunotherapy with immune checkpoint inhibitors, there has not been enough investigation to determine its potential.

Small clinical trials have suggested that checkpoint inhibitors have limited efficacy, but the truth may be that they are not being used appropriately in order to be used to its highest potential.


Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of modern immunotherapies in the landscape of mantle cell lymphoma (MCL).

Immunotherapy has been in the field of MCL for a long time, Martin explains, with rituximab (Rituxan). However, when discussing the modern era of immunotherapy with immune checkpoint inhibitors, there has not been enough investigation to determine its potential.

Small clinical trials have suggested that checkpoint inhibitors have limited efficacy, but the truth may be that they are not being used appropriately in order to be used to its highest potential.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x